Stylized representation of the NextPoint logo icon, featuring immunotherapy-related cellular imagery

expanding the potential of immunotherapy

One pathway,
many possibilities

NextPoint’s world renowned scientific founders recently discovered a novel checkpoint axis that is independent of PD-1/L1 and is present at high levels in many hard to treat cancers. This revolutionary discovery represents a previously unknown gateway to modulating both the adaptive and innate immune systems to find and destroy cancer cells.

Founded by MPM Capital, NextPoint Therapeutics has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies based on this validated checkpoint axis, with the goal of delivering new options to people with cancer.

world-class team.

scientific founders.

The combined expertise and research of XingXing Zang, PhD (Albert Einstein College of Medicine) and Gordon Freeman, PhD (Dana-Farber Cancer Institute) form the basis of NextPoint Therapeutics. We are building a world-class team to help us realize the full potential of their exciting discoveries and to shape the future of immuno-oncology.

XingXing Zang, PhD

Albert Einstein College of Medicine

Gordon Freeman, PhD

Dana-Farber Cancer Institute

leadership.

Detlev Biniszkiewicz, PhD

Chief Executive Officer

Scott Chappel, PhD

Chief Scientific Officer

Paul Conrad, PhD, MBA

Chief Business Officer

Briggs Morrison, MD

Interim Chief Medical Officer

investors & partners.

Logo for MPM Capital, powering breakthroughs in life sciences
Logo for Dana-Farber Cancer Institute, Binney Street Capital
Logo for Simcere